{"id":124871,"date":"2026-06-22T09:01:50","date_gmt":"2026-06-22T03:31:50","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=124871"},"modified":"2026-06-22T09:01:52","modified_gmt":"2026-06-22T03:31:52","slug":"avience-biomedicals-ipo-allotment-status","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-allotment-status\/","title":{"rendered":"Avience Biomedicals IPO Allotment Status: How to Check via Skyline Financial, NSE Portal or Broker"},"content":{"rendered":"
<\/div>\n

Avience Biomedicals IPO allotment pending. NSE SME listing. Price Rs 196-208. GMP Rs 85. Registrar: Skyline Financial Services. Check via NSE portal or registrar using PAN.<\/em><\/p>\n

Investors who applied for the Avience Biomedicals IPO will be able to check their allotment status on the official NSE SME IPO allotment portal or through the registrar Skyline Financial Services Private Limited once the basis of allotment is finalised. The Avience Biomedicals IPO is a Rs 30.24 crore 100% fresh issue at a price band of Rs 196 to Rs 208 per share, proposing to list on the NSE SME platform. With the grey market premium running at Rs 85 on Day 3 of GMP tracking, allottees are positioned to potentially receive allotment at a significant discount to the expected listing price of approximately Rs 293. Kunal Singla, Associate Director at Univest, recommends that Avience Biomedicals IPO allottees plan their post-allotment strategy carefully, noting that while the GMP of Rs 85 is encouraging, actual listing prices on the NSE SME platform can deviate significantly from GMP-implied levels, particularly for smaller issues where sell-on-listing volumes can overwhelm initial buy interest.
\nClick Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n